دورية أكاديمية
Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia.
| العنوان: | Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. |
|---|---|
| المؤلفون: | Pierpaolo Correale, Massimo Caracciolo, Federico Bilotta, Marco Conte, Maria Cuzzola, Carmela Falcone, Carmelo Mangano, Antonella Consuelo Falzea, Eleonora Iuliano, Antonella Morabito, Giuseppe Foti, Antonio Armentano, Michele Caraglia, Antonino De Lorenzo, Michail Sitkovsky, Sebastiano Macheda |
| المصدر: | PLoS ONE, Vol 15, Iss 10, p e0239692 (2020) |
| بيانات النشر: | Public Library of Science (PLoS), 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Medicine LCC:Science |
| مصطلحات موضوعية: | Medicine, Science |
| الوصف: | BackgroundSARS-Cov2 infection may trigger lung inflammation and acute-respiratory-distress-syndrome (ARDS) that requires active ventilation and may have fatal outcome. Considering the severity of the disease and the lack of active treatments, 14 patients with Covid-19 and severe lung inflammation received inhaled adenosine in the attempt to therapeutically compensate for the oxygen-related loss of the endogenous adenosine→A2A adenosine receptor (A2AR)-mediated mitigation of the lung-destructing inflammatory damage. This off label-treatment was based on preclinical studies in mice with LPS-induced ARDS, where inhaled adenosine/A2AR agonists protected oxygenated lungs from the deadly inflammatory damage. The treatment was allowed, considering that adenosine has several clinical applications.Patients and treatmentFourteen consecutively enrolled patients with Covid19-related interstitial pneumonitis and PaO2/FiO2 ratioResultsThe treatment was well tolerated with no hemodynamic change and one case of moderate bronchospasm. A significant increase (> 30%) in the PaO2/FiO2-ratio was reported in 13 out of 14 patients treated with adenosine compared with that observed in 7 out of52 patients in the control within 15 days. Additionally, we recorded a mean PaO2/FiO2-ratio increase (215 ± 45 vs. 464 ± 136, P = 0.0002) in patients receiving adenosine and no change in the control group (210±75 vs. 250±85 at 120 hours, P>0.05). A radiological response was demonstrated in 7 patients who received adenosine, while SARS-CoV-2 RNA load rapidly decreased in 13 cases within 7 days while no changes were recorded in the control group within 15 days. There was one Covid-19 related death in the experimental group and 11in the control group.ConclusionOur short-term analysis suggests the overall safety and beneficial therapeutic effect of inhaled adenosine in patients with Covid-19-inflammatory lung disease suggesting further investigation in controlled clinical trials. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1932-6203 |
| العلاقة: | https://doaj.org/toc/1932-6203Test |
| DOI: | 10.1371/journal.pone.0239692 |
| الوصول الحر: | https://doaj.org/article/c0fee749597d490eb62cc6d4417d8d39Test |
| رقم الانضمام: | edsdoj.0fee749597d490eb62cc6d4417d8d39 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0239692 |